Assessment of BC UDCs across different treatments and proteomic profile of urine across disease stage. (A) Heatmap of top DEGs per cell cluster of UDCs from the BC patient who underwent BCG induction therapy. (B and C) (B) Volcano plot and (C) GSEA representing DEGs between UDCs from the Week (W) 1 pre-BCG and Week 6 post-BCG collections. (D and E) Volcano plot of DEGs between urothelial cells from BC Patient 7 before and after chemotherapy (D) in tumor and (E) in urine. (F) Bar plots of UDC composition across HDs and NMIBC and MIBC patients. (G) Hierarchically clustered heatmap of NPX levels of all 92 analytes of the Olink Immuno-Oncology panel in 10 HDs, 15 NMIBC, and 10 MIBC patients. (H) Bar plots comparing NPX levels of IFNγ, granzyme B, IL-8, and IL-6 in the urine across HD, NMIBC, and MIBC patients. Wilcoxon tests were performed (P value: * <0.05, ** <0.01, *** <0.001).
Figure S5.

Assessment of BC UDCs across different treatments and proteomic profile of urine across disease stage. (A) Heatmap of top DEGs per cell cluster of UDCs from the BC patient who underwent BCG induction therapy. (B and C) (B) Volcano plot and (C) GSEA representing DEGs between UDCs from the Week (W) 1 pre-BCG and Week 6 post-BCG collections. (D and E) Volcano plot of DEGs between urothelial cells from BC Patient 7 before and after chemotherapy (D) in tumor and (E) in urine. (F) Bar plots of UDC composition across HDs and NMIBC and MIBC patients. (G) Hierarchically clustered heatmap of NPX levels of all 92 analytes of the Olink Immuno-Oncology panel in 10 HDs, 15 NMIBC, and 10 MIBC patients. (H) Bar plots comparing NPX levels of IFNγ, granzyme B, IL-8, and IL-6 in the urine across HD, NMIBC, and MIBC patients. Wilcoxon tests were performed (P value: * <0.05, ** <0.01, *** <0.001).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal